Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity

Chen et al., Biomedical Chromatography, doi:10.1002/bmc.5996
Aug 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of molnupiravir induced liver injury. Molnupiravir treatment may disrupt metabolic homeostasis and cause liver injury by increasing levels of certain metabolites and activating inflammatory pathways.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-15.
Chen et al., 23 Aug 2024, peer-reviewed, 8 authors.
This PaperMolnupiravirAll
{ 'indexed': {'date-parts': [[2024, 8, 24]], 'date-time': '2024-08-24T00:31:18Z', 'timestamp': 1724459478158}, 'reference-count': 42, 'publisher': 'Wiley', 'license': [ { 'start': { 'date-parts': [[2024, 8, 23]], 'date-time': '2024-08-23T00:00:00Z', 'timestamp': 1724371200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'funder': [ { 'DOI': '10.13039/501100012166', 'name': 'National Key Research and Development Program of China', 'doi-asserted-by': 'publisher', 'award': ['2021YFF0702003'], 'id': [{'id': '10.13039/501100012166', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100013365', 'name': 'West China Hospital, Sichuan University', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/501100013365', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}], 'content-domain': { 'domain': ['analyticalsciencejournals.onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Molnupiravir (MO) is a pyrimidine nucleoside ' 'anti‐SARS‐CoV‐2 drug. MO treatment could cause mild liver injury. However, the underlying ' 'mechanism of MO‐induced liver injury and the metabolic pathway of MO in vivo are unclear. In ' 'this study, metabolomics analysis and molecular biology methods were used to explore these ' 'issues. Through metabolomics analysis, it was found that the homeostasis of pyrimidine, ' 'purine, lysophosphatidylcholine (LPC), and amino acids in mice was destroyed after MO ' 'treatment. A total of 80 changed metabolites were detected. Among these changed metabolites, ' '4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 was related to the elevation of alkaline ' 'phosphatase (ALP), interleukin‐6 (IL6), and nuclear factor kappa‐B (NF‐κB). The levels of ' '4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 in plasma were positively correlated with ' 'their levels in the liver, suggesting that these metabolites were associated with MO‐induced ' 'liver injury. MO treatment could increase NHC and cytidine levels, activate cytidine ' 'deaminase (CDA), and increase LPC levels. CDA and LPC could increase the mRNA expression ' 'level of toll‐like receptor (TLR). The current study indicated that the elevation of hepatic ' 'TLR may be an important reason for MO leading to the liver injury.</jats:p>', 'DOI': '10.1002/bmc.5996', 'type': 'journal-article', 'created': {'date-parts': [[2024, 8, 23]], 'date-time': '2024-08-23T09:34:21Z', 'timestamp': 1724405661000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic ' 'disorders and hepatotoxicity', 'prefix': '10.1002', 'author': [ { 'given': 'Jiahui', 'family': 'Chen', 'sequence': 'first', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}, { 'name': 'Department of Gastroenterology &amp; Hepatology, Laboratory of ' 'Hepato‐intestinal Diseases and Metabolism, Frontiers Science ' 'Center for Disease‐Related Molecular Network, and State Key ' 'Laboratory of Respiratory Health and Multimorbidity, West China ' 'Hospital Sichuan University Chengdu Sichuan China'}]}, { 'given': 'Liqiong', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}, { 'name': 'Department of Gastroenterology &amp; Hepatology, Laboratory of ' 'Hepato‐intestinal Diseases and Metabolism, Frontiers Science ' 'Center for Disease‐Related Molecular Network, and State Key ' 'Laboratory of Respiratory Health and Multimorbidity, West China ' 'Hospital Sichuan University Chengdu Sichuan China'}]}, { 'given': 'Bin', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}]}, { 'given': 'Qi', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology &amp; Hepatology, Laboratory of ' 'Hepato‐intestinal Diseases and Metabolism, Frontiers Science ' 'Center for Disease‐Related Molecular Network, and State Key ' 'Laboratory of Respiratory Health and Multimorbidity, West China ' 'Hospital Sichuan University Chengdu Sichuan China'}]}, { 'given': 'Yan', 'family': 'Cheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}, { 'name': 'Department of Gastroenterology &amp; Hepatology, Laboratory of ' 'Hepato‐intestinal Diseases and Metabolism, Frontiers Science ' 'Center for Disease‐Related Molecular Network, and State Key ' 'Laboratory of Respiratory Health and Multimorbidity, West China ' 'Hospital Sichuan University Chengdu Sichuan China'}]}, { 'given': 'Dongmei', 'family': 'Yan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}]}, { 'given': 'Hongning', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academician Workstation Jiangxi University of Chinese Medicine ' 'Nanchang China'}]}, { 'given': 'Fei', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology &amp; Hepatology, Laboratory of ' 'Hepato‐intestinal Diseases and Metabolism, Frontiers Science ' 'Center for Disease‐Related Molecular Network, and State Key ' 'Laboratory of Respiratory Health and Multimorbidity, West China ' 'Hospital Sichuan University Chengdu Sichuan China'}]}], 'member': '311', 'published-online': {'date-parts': [[2024, 8, 23]]}, 'reference': [ { 'key': 'e_1_2_9_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/19490976.2022.2102878'}, {'key': 'e_1_2_9_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1210/en.2007-1747'}, {'key': 'e_1_2_9_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/EVIDoa2100044'}, {'key': 'e_1_2_9_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00280-003-0695-8'}, {'key': 'e_1_2_9_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-020-73966-5'}, { 'key': 'e_1_2_9_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0006-2952(86)90625-8'}, { 'key': 'e_1_2_9_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.toxlet.2022.04.002'}, { 'key': 'e_1_2_9_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.intimp.2011.04.023'}, {'key': 'e_1_2_9_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep46658'}, {'key': 'e_1_2_9_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/1462-2920.15025'}, { 'key': 'e_1_2_9_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0950-3552(05)80289-5'}, {'key': 'e_1_2_9_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/sciadv.abb5813'}, {'key': 'e_1_2_9_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2021.779135'}, { 'key': 'e_1_2_9_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abl7430'}, { 'key': 'e_1_2_9_16_1', 'doi-asserted-by': 'crossref', 'unstructured': 'Fountain‐Jones N. M. Vanhaeften R. Williamson J. Maskell J. Chua I. L. ' 'J. Charleston M. &Cooley L.(2022).Antiviral treatments lead to the rapid ' 'accrual of hundreds of SARS‐CoV‐2 mutations in immunocompromised ' 'patients. medRxivhttps://doi.org/10.1101/2022.12.21.22283811', 'DOI': '10.1101/2022.12.21.22283811'}, {'key': 'e_1_2_9_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/intimm/dxy075'}, {'key': 'e_1_2_9_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1194/jlr.M700184-JLR200'}, {'key': 'e_1_2_9_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/mmr.2015.4312'}, {'key': 'e_1_2_9_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4254/wjh.v8.i1.1'}, {'key': 'e_1_2_9_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phrs.2020.104752'}, {'key': 'e_1_2_9_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiac477'}, {'key': 'e_1_2_9_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/tx300298m'}, { 'key': 'e_1_2_9_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1574888X12666171012141908'}, {'key': 'e_1_2_9_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2023.1253799'}, {'key': 'e_1_2_9_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/cells11233791'}, {'key': 'e_1_2_9_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.lfs.2020.117443'}, {'key': 'e_1_2_9_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.12998/wjcc.v6.i10.355'}, {'key': 'e_1_2_9_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms24098065'}, {'key': 'e_1_2_9_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12263-019-0653-7'}, {'key': 'e_1_2_9_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-022-04396-8'}, {'key': 'e_1_2_9_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-023-06073-w'}, { 'key': 'e_1_2_9_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2019.104597'}, {'key': 'e_1_2_9_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-023-06649-6'}, { 'key': 'e_1_2_9_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1517/17425255.2015.985648'}, {'key': 'e_1_2_9_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1124/dmd.122.000918'}, {'key': 'e_1_2_9_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s40121-023-00915-w'}, {'key': 'e_1_2_9_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2022.855496'}, {'key': 'e_1_2_9_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-021-03312-w'}, { 'key': 'e_1_2_9_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/microorganisms8121899'}, {'key': 'e_1_2_9_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18632/oncotarget.20774'}, {'key': 'e_1_2_9_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-023-37459-z'}, {'key': 'e_1_2_9_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiab247'}], 'container-title': 'Biomedical Chromatography', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2024, 8, 23]], 'date-time': '2024-08-23T09:34:28Z', 'timestamp': 1724405668000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.5996'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 8, 23]]}, 'references-count': 42, 'alternative-id': ['10.1002/bmc.5996'], 'URL': 'http://dx.doi.org/10.1002/bmc.5996', 'relation': {}, 'ISSN': ['0269-3879', '1099-0801'], 'subject': [], 'container-title-short': 'Biomedical Chromatography', 'published': {'date-parts': [[2024, 8, 23]]}, 'assertion': [ { 'value': '2024-06-16', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-08-13', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-08-23', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit